Interest of Molecular Analysis of Cerebral Thrombi in Determining the Prognosis and Etiology of Cerebral Infarction

Assistance Publique Hopitaux De Marseille311 enrolled

Overview

The MATISSE (Molecular Analysis of Thrombus for Ischemic Stroke prognosis and Etiology) project evaluates the hypothesis that the molecular composition of cerebral thrombus in metabolites, lipids, and proteins conditions the clinical prognosis at 3 months of the infarction and informs on its etiological subtype

Study Type

OBSERVATIONAL

Enrollment

311

Conditions

Ischemic Stroke

Interventions

Thrombi and blood analysesOTHER

Thrombi and blood will be collected during thrombectomy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female 18 years of age or older; * Patient with a cerebral infarction documented by brain imaging who received endovascular treatment by mechanical thrombectomy; * Patient for whom it was possible to collect cerebral thrombus for LC-MS analysis during mechanical thrombectomy: * Patient who was informed of the study and formulated a non-opposition to participation. If not, patient for whom a relative was informed and formulated a non-opposition. Exclusion Criteria: * Patient with a cerebral infarction documented by cerebral imaging, having benefited from an endovascular treatment with mechanical thrombectomy that did not allow the extraction of a cerebral thrombus. * Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breast-feeding women, persons deprived of liberty, under guardianship or curatorship

Locations (4)

CHU Martinique

Fort-de-France, France

RECRUITING

Stroke Center

Marseille, France

RECRUITING

CHU Guadeloupe

Pointe à Pitre, France

RECRUITING

Outcomes

Primary Outcomes

Determination and validation of molecular signatures, obtained by LC-MS analysis of cerebral thrombi, predictive of the excellent clinical prognosis

Rankin score (0 to 6, 6 meaning worse outcome)

Time frame: 3 months after the cerebral infarction

Secondary Outcomes

Determination and validation of molecular signatures, obtained by LC-MS analysis

ASCOD (atherosclerosis, small vessel disease (SVD), cardioembolism, other and dissection) description (0 to 9, 9 meaning insufficient assessment to determine the presence or absence of the disease)

Time frame: 7 days after the cerebral infarction

Determination and validation of molecular signatures, obtained by LC-MS analysis

ASCOD (atherosclerosis, small vessel disease (SVD), cardioembolism, other and dissection) description (0 to 9, 9 meaning insufficient assessment to determine the presence or absence of the disease)

Time frame: 3 months after the cerebral infarction

Severe intracranial hemorrhage

Heildeberg classification (0 to 3d, 3d meaning subdural hemorrhage)

Time frame: 3 months after the cerebral infarction

Recovery of autonomy in walking

Parker score (0 to 9, 9 meaning better outcome)

Time frame: 3 months after the cerebral infarction

Recovery of autonomy in walking

Parker score (0 to 9, 9 meaning better outcome)

Time frame: 7 days after the cerebral infarction

Early Neurological Deterioration

Worsening of at least 4 points in the NIHSS (National Institutes of Health Stroke Scale) score (0 meaning better outcome, 0 to 42)

Central Contacts

Emilie Doche

CONTACT

04 91 38 78 65 emilie.doche@ap-hm.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.